$WELL

Gundlach Andrew purchased $2.4M of WELL (indirect holdings)

Gundlach Andrew purchased 10,000 indirectly-held shares of WELLTOWER INC. (WELL) at an average of $240.76 ($239.47–$242.06, $2.41M total) across 4 trades over 2026-08-25 to 2026-08-26.

Original reporting
SEC EDGAR · Gundlach Andrew
Published Aug 27, 2026, 8:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$WELL
Bullish
medium confidence
Mentioned
$WELL
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WELLBullishMed
01

Why it matters

The director's purchase adds 30,000 shares to his holdings, indicating personal confidence but limited market effect.

02

Market read

Minor insider buying; may be noted by REIT analysts but unlikely to drive significant price movement.

03

What to watch

Potential upcoming REIT acquisitions or dividend policy changes not disclosed.

Relevance 7/10Novelty 6/10Timing: post‑filing today

Background

Form 4 filing discloses insider transactions; WELL is a large‑cap healthcare REIT.

Company-level read

Ticker impact

$WELLBullishMedium confidence
Context

Director Andrew Gundlach bought 10,000 WELL shares for $2.4M via open‑market purchases on 2026‑08‑25/26.

Expected impact

Potential slight upside pressure, unlikely to move price materially.

Evidence & confidence

Purchase size is small relative to market cap; director ownership increase modest.

Market effects

Limited; insider activity may be noted by healthcare REIT investors.

None

None

Counterpoint

Insider purchase could be a routine portfolio rebalancing, not a strong buy signal.

Key entities

  • Andrew Gundlach

    Director of WELLTOWER INC. who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WELLMed

Welltower Stock: Analyst Estimates & Ratings

Welltower Inc. (WELL) is a healthcare REIT. The article cites WELL’s stock performance versus the S&P 500 and REZ, and attributes gains to senior housing NOI growth, occupancy recovery, pricing power, demographics, and capital recycling. It reports Q2 FFO of $1.60 vs $1.55 expected, revenue $3.5B, and full-year FFO guidance $3.11 to $3.19. Analysts rate it a “Strong Buy” with a KeyBanc $275 target.

$WELLMed

Welltower Reports Revenue and Income Growth From Senior Housing Investments – Commercial Observer

Welltower reported Q2 2026 results and balance sheet progress. On an earnings call, the REIT cited acquisitions including Amica Senior Lifestyles (38 communities, $1.91B) and a July 2 Canada deal (five development properties, ~$459M). It also disposed of $7.2B outpatient medical properties. Q2 revenue rose to $3.54B, FFO to $1.60/share, and net income to $12.2B.

$KOMed

Stocks making the biggest moves premarket: Coca-Cola, Sherwin-Williams, Johnson & Johnson & more

Premarket movers included Coca-Cola, Sherwin-Williams, Hilton, Johnson & Johnson, Corning, Cadence Design Systems, Rambus, Universal Health Services, Welltower, Happen (formerly LendingClub), and Cincinnati Financial. Key catalysts were earnings beats or misses and guidance changes, including J&J’s $5.5 billion talc settlement and Coca-Cola’s raised outlook after EPS and revenue topped estimates.